Archive for 2015

Monday's After-Hours Movers Led By Chinese Internet Stocks, Show Carnival, Infoblox And Thor

Courtesy of Benzinga.

Related SCVL
Must Watch Stocks for November 30, 2015
Earnings Scheduled For November 30, 2015
Shoe Carnival (SCVL) Q3 2015 Results – Earnings Call Webcast (Seeking Alpha)

Related BLOX
Must Watch Stocks for November 30, 2015
Earnings Scheduled For November 30, 2015
Infoblox soars after beat, buyback, and strong guidance (Seeking Alpha)

Shares of Shoe Carnival, Inc. (NASDAQ: SCVL) were trading up about 3 percent in Monday's after-hours session, following the announcement of the company's third quarter financial results. The small-cap family footwear retailer reported earnings of $0.47 per share, below the Street's consensus of $0.48 per share. However, revenue of $269.71 million came in ahead of estimates that called for $265.85 million.

Infoblox Inc (NYSE: BLOX) was up about 17 percent after the bell rang. The small-cap company reported earnings of $0.13 per share on revenue of $94 million, up 40.9 percent. However, the Street was expecting much lower results. Consensus, in line with management’s guidance, called for earnings of $0.06 per share on sales of $87.9 million.

Thor Industries, Inc. (NYSE: THO) gained more than 3.5 percent. The company reported sales of $1.03 billion, up 12 percent year-over-year; net income of $50.7 million, up 29 percent; diluted earnings per share of $0.97, up 33 percent; and gross profit margins of 14.8 percent, up from 12.8 percent.

On the other hand, Chinese Internet stocks were tumbling on Monday afternoon. Among the biggest decliners: SINA Corp (NASDAQ: SINA) down more than 1.3 percent; Baidu Inc (ADR) (NASDAQ: BIDU) down over 1.8 percent; Sohu.com Inc (NASDAQ: SOHU) down about 2.7 percent;Alibaba Group Holding Ltd (NYSE: BABA) down 0.3 percent; NetEase Inc (ADR) (NASDAQ: NTES) down almost 2 percent; and 58.com Inc (ADR) (NYSE: WUBA), down 1 percent.

Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.

Posted-In: Earnings News After-Hours Center Movers





Leerink Highlights Biotechs Poised To Benefit From ASH Conference

Courtesy of Benzinga.

Leerink Highlights Biotechs Poised To Benefit From ASH Conference

Related ALNY
ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray
Chardan Sees Promise Of ALN-PCSsc, Initiates The Medicines Co. With Buy

Related JUNO
Ronnie Moas Downgrades Kite Pharma, Sees $100 Stock Price Through 2018
Here's Why Biotechs Fell On Monday

  • On Monday, Leerink issued a report previewing the American Society of Hematology annual meeting, which will be held from December 5 to December 8.
  • Leerink believes that this meeting will have meaningful clinical updates for Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Juno Therapeutics Inc (NASDAQ: JUNO) and Karyopharm Therapeutics Inc (NASDAQ: KPTI).
  • Leerink reiterated their OP rating for all three issues.
  • Michael Schmidt and Jonathan Chang, analysts at Leerink, highlighted Juno, Karyopharm and Alnylam in their report ahead of the annual ASH Conference.

    Alnylam

    “ALNY will present important updates from ALN-CC5 (complement-mediated diseases) and ALN-AT3 (bleeding disorders) Phase I trials, respectively, including multi-dose cohorts, which should further validate early clinical results presented from either agent this summer.”

    Related Link: La Jolla Pharmaceutical Company Announces Notice Of Allowance For U.S. Patent Covering

    Juno

    “Six ASH presentations for JUNO will include updates from JCAR014 (anti-CD19, FHCRC) trials in NHL, chronic lymphocytic leukemia (CLL)… We’d expect updates at ASH to include more pts and data on durability in NHL, which could help position JUNO’s product vs. competitors.”

    Karyopharm

    “Clinical data presentations on selinexor combinations include (1) a summary of Ph II dose finding trials showing that a flat dose of 60mg selinexor twice weekly provides the best risk-benefit profile.”

    Overall, the analysts believe that this presentation will contain meaningful data that could serve as catalysts for these companies going forward, particularly as it relates to Phase 1 and Phase 2 data. Positive data may validate early clinical results leading to positive investor sentiment.

    Alnylam Pharmaceuticals shares recently traded at $105.37, down 1.87 percent on Monday.

    Juno Therapeutics recently traded at $55.83, down 0.89 percent on Monday.

    Karyopharm Therapeutics shares recently traded at $18.38, down 3.16 percent on Monday.

    Image Credit: Public Domain

    Latest Ratings for ALNY

    Date Firm Action From To
    Nov 2015 Leerink Swann Maintains Outperform
    Oct 2015 Jefferies Initiates Coverage on Buy
    Aug 2015 Leerink Swann Maintains Outperform

    View More Analyst Ratings for ALNY
    View the Latest Analyst Ratings

    Posted-In: Analyst Color Biotech Long Ideas Health Care Reiteration Top Stories Analyst Ratings Trading Ideas Best of Benzinga





    Buckingham: United Continental Still Has 73% Upside

    Courtesy of Benzinga.

    Buckingham: United Continental Still Has 73% Upside
    Related UAL
    12 Ways To Invest In Airlines
    Thanksgiving Could Be Busiest For Air Travel Since The Recession
    Alan Fournier Sells Workday, SunEdison Stakes in 3rd Quarter (GuruFocus)
    Related
    These Analysts See Chilly Winter For Airline Stocks
    Cowen Met With Southwest And American Airlines Management; Prefer This Stock

  • In a report issued Monday, Buckingham Research analysts Daniel McKenzie and Scott Park shared a look into United Continental Holdings Inc (NYSE: UAL) after its pilot agreement.
  • While the new conditions will pull costs forward, the firm did not alter its 2016 pre-tax outlook.
  • Moreover, the experts reiterated a Buy rating and $98 price target on the stock.
  • After United Continental reached a new agreement with its pilots granting them a wage increase of roughly 13 percent (some sources have said 16 percent) effective January 1, 2016, analysts at Buckingham research looked into the company and decided to leave their 2016 pre-tax outlook unaffected.

    However, they estimate the deal will generate an incremental cost headwind of ~$200 million–$270 million.

    All Things The Same…

    Ceteris paribus, the deal should impact the firm’s 2016 EPS estimate by 4 to 6 percent, or by $0.35–$0.45 per share, leaving United wages (ex profit-sharing) at American Airlines Group Inc (NASDAQ: AAL) levels – to which profit sharing is then added.

    Related Link: Barclays Cuts Target On Spirit Airlines, Says It’s No Longer A Top Pick

    “Net net, the pilots get a very generous mid-contract raise; mgmt. buys labor peace and possibly better operations (and on this point, we don't expect mgmt. to quantify the cost of a bad operation, but in the past we've quantified $1 billion in revenue book-away),” the report expounded.

    At this point, however, the analysts are not considering other labor deals with flight attendants or other groups in the company, although they could eventually affect their non-fuel CASM projection next year.

    Moreover, the experts noted that the decision to “pull pilot expense…
    continue reading





    An Inexpensive Small-Cap ETF For December Gains

    Courtesy of Benzinga.

    An Inexpensive Small-Cap ETF For December Gains
    Related IJR
    Of Rate Hikes And Small-Cap ETFs
    Active Management Mediocrity Continues
    There's still time to go small (Seeking Alpha)

    Tuesday marks the start of December, and with the arrival of the last month of the year imminent, there has been plenty of chatter about the seasonal efficacy of small-cap stocks and corresponding exchange-traded funds.

    Of course, it is the January Effect that spurs increased small-cap chatter at this time of the year. The January Effect is the notion that small-caps lead the market higher in January, setting the table for a positive performance by equities for the year.

    The thing is, however, the January Effect has been starting earlier and earlier, so investors should consider mulling exchange-traded funds such as the iShares Russell 2000 Index (ETF)(NYSE: IWM).

    IWM is the largest small-cap ETF.

    Related Link: Small-Cap Seasonality: It’s The Right Time For This ETF

    Looking Beyond IWM: IJR

    Cost-conscious investors looking to make a long-term commitment to a small-cap ETF should also consider the $17.4 billion iShares S&P SmallCap 600 Index (ETF) (NYSE: IJR). IJR, which is a member of the low-fee iShares core lineup, tracks the S&P SmallCap 600 Index.

    “Aided by a strong November, the S&P SmallCap 600 Index, the benchmark IJR seeks to track, has had relatively strong run thus far in 2015. Still, we believe small-cap stocks will experience above-average earnings growth in 2016 that in some cases is not fully reflected in valuations. While the small cap index is trading at 18.6X 2016 estimates, higher than the 18.1X for the mid-cap index and 16.5X for the S&P 500 index, the P/E-growth rate of 1.3X is at a discount to its larger peers (1.6X for mid caps and 1.5X for S&P 500 index).

    “Lastly, in Presidential election years since 1980, small caps have risen on average 10.9 percent, more than double the 4.2 percent gain for the S&P 500 index, according to S&P Capital IQ's equity strategist Sam Stovall,” said S&P Capital IQ in a note out Monday.

    IJR, which actually…
    continue reading





    Microsoft The Long-Term Winner In Cloud? This Analyst Thinks So

    Courtesy of Benzinga.

    Microsoft The Long-Term Winner In Cloud? This Analyst Thinks So

    Related MSFT
    Benzinga's Top Upgrades
    Rate-Proofing A Portfolio With ETFs
    Small Caps Show Early Strength; Microsoft, Merck, Fitbit Rising (Investor’s Business Daily)

    • Shares of Microsoft Corporation (NASDAQ: MSFT) are up 16 percent year-to-date, and are trading close to their 52-week high of $54.98.
    • Raymond James’ Michael Turits upgraded the rating on the company from Market Perform to Strong Buy, with a price target of $62.
    • Microsoft is expected to emerge as a strong player in the cloud segment with its ability to integrate various services, Turits mentioned.

    Microsoft is fast emerging as one of the only “hyperscale” hybrid cloud vendors able to integrate Infrastructure-as-a-Service [IaaS], Platform-as-a-Service [PaaS] and Software-as-a-Service [PaaS] with a significant installed base of on-premise server and client software, analyst Michael Turits stated.

    About 17 percent of Microsoft’s revenues in FY16 are expected to come from cloud.

    Turits added, “[W]e forecast a 6% total revenue CAGR FY16-FY18E, including 6% for Productivity and Business Processes (Office/Dynamics), 9% for Intelligent Cloud (Azure/Server) and 3% for More Personal Computing (Windows -5%, non-Windows +6%), although off lowered FY16 estimates.”

    While opex controls are expected to offset to some extent the gross margin decline through FY18 on the shift to cloud, the company is expected to post flat operating margins and 6 percent EBIT growth with long-term EPS growth expected at at-least 8 percent after share buybacks, the Raymond James report stated.

    Turits expects Azure to put Microsoft at par with hyperscale vendors like Amazon Web Services. He wrote, “We believe CEO Satya Nadella’s aggressively open strategy toward non-Microsoft platforms (Linux, containers) will make Azure a dominant PaaS as well as IaaS.”

    The revenue and non-GAAP EPS estimates for FY16 have been reduced from $93,288 million to $91,803 million and from $2.74 to $2.62, respectively, to account for cloud and currency impacts.

    Latest Ratings for MSFT

    Date Firm Action From To
    Nov 2015 Raymond James Upgrades Market Perform Strong Buy
    Nov 2015 Piper Jaffray Maintains Overweight
    Oct 2015 Bank of America Upgrades Neutral Buy

    View More Analyst Ratings for MSFT
    View the Latest Analyst Ratings

    Posted-In: Michael Turits Raymond JamesAnalyst Color Long Ideas Upgrades Analyst Ratings Trading Ideas Best of Benzinga





    3 Reasons Guggenheim Sees $100 Oil By 2018

    Courtesy of Benzinga.

    3 Reasons Guggenheim Sees $100 Oil By 2018
    Related CLR
    Benzinga's Top Upgrades
    Yum! Brands, Adobe Plummeting In Tuesday's After-Hours Session
    Related DVN
    Benzinga's Top Upgrades
    Earnings Scheduled For November 3, 2015

  • Guggenheim projects crude oil prices will recover to $100/bbl by 2018.
  • Further global production disruptions could result in an even faster recovery.
  • The firm sees several supply-driven catalysts to a strong recovery in oil.
  • In a new report, Guggenheim analyst Michael LaMotte upgraded the oil services sector from Neutral to Buy based on the firm’s belief that oil prices are set for a sharp rebound in coming years.

    Guggenheim is now calling for a return to $100/bbl oil by 2018, a move that would have broad market impacts extending far beyond the oil services sector.

    Here’s a look at three reasons Guggenheim predicts such a sharp rise in oil prices.

    1. Delays In Production Turnaround

    LaMotte predicts that it will be more difficult than anticipated to re-stimulate production outside of the United States, Russia and OPEC nations following at least two years of plummeting E&P capex. “Specifically, we expect the net, managed decline rate for this 27.7 mmbd of production to decline -2.5 percent pa beginning next year,” LaMotte explained.

    2. Wars In Syria And Iraq

    LaMotte believes that the ongoing conflicts in Syria and Iraq will continue to deflect investment in the Gulf away from oil production and into military and social services investment. In addition, LaMotte sees only 1 mmbd production gain from Iran over the next couple of years and believes that any amount of production beyond 3.8 mmbd will require years of upfront investment.

    3. Only Modest U.S. Tight Oil Production Growth

    A combination of slower drillbit response in 2016 and declining well productivity in 2017 likely means that U.S. tight oil production will be limited to modest growth in coming years.

    E&P Stocks To Buy

    While Guggenheim has upgraded nearly the entire oil services space to Buy, the firm also sees several E&P stocks with large upsides that could witness a share price liftoff when…
    continue reading





    Galil Medical and Perseon Corporation Announce Tender Offer/Merger Information Call For Dec 2 2015

    Courtesy of Benzinga.

    Galil Medical (“Galil”), a global leader in delivering innovative cryotherapy ablation solutions, and Perseon Corporation (NASDAQ: PRSN) (NASDAQ:PRSNW) (“Perseon” or “The Company”), a leading provider of medical systems that utilize energy to treat cancer, today announced that management will hold a Tender Offer/Merger Information conference call on Wednesday, December 2, 2015 at 11:00 a.m. Eastern Time/8:00 a.m. Pacific Time. Commentary will include content from the Schedule TO and Schedule 14D-9. Perseon management will also provide an update on the company’s cash balance.

    Individuals interested in listening to the conference call may do so by visiting the Investor Relations section of Perseon’s website at http://perseonmedical.com/ or by dialing 877-270-2148 from the United States, or 412-902-6510 from outside the United States, and referencing “Perseon Corporation”.

    A telephone replay will be available through December 16, 2015, by dialing 877-344-7529 from the United States, or 412-317-0088 from outside the United States, and entering conference ID 10076824. A webcast replay will be available for 90 days. A transcript of the call will also be available on the Investor Relations section of Perseon’s website.

    Posted-In: News M&A Press Releases





    SunTrust's Bob Peck Highlights Top 10 Candidates To Be Yahoo's Next CEO

    Courtesy of Benzinga.

    SunTrust's Bob Peck Highlights Top 10 Candidates To Be Yahoo's Next CEO

    Related YHOO
    Jon Najarian Is Bullish On Yahoo
    Bob Peck: Activist's Concerns At Yahoo Are Warranted
    Internet's Q3 Was Pass, Fail (Investor’s Business Daily)

    • Yahoo! Inc. (NASDAQ: YHOO) shares are down 35 percent year-to-date, slipping below the $50 mark on January 9 and declining steadily after that.
    • SunTrust Robinson Humphrey’s Robert S. Peck maintained a Buy rating for the company, with a price target of $40.
    • Levinsohn, Rosensweig and Sandberg are among the top 10 suggested candidates for the company’s CEO, Peck said.

    Several media reports have been speculating on the stability of Yahoo’s senior management, in particular that of its current CEO Marissa Mayer.

    Based on talks with industry participants and investors, analyst Robert Peck cited 5 key attributes that a potential candidate for the company’s CEO could be evaluated on:

    1. Public CEO experience
    2. Familiarity with Yahoo, its core business, unique challenges and opportunities
    3. Media background
    4. Technology experience
    5. Turnaround executions or strong operational experience.

    “While this is not an exhaustive list, we agree with investors centering around these themes,” Peck wrote.

    Based on the 5 key attributed, a list of about 40 potential candidates was made. The Top 10 most cited, albeit in no particular order, were:

    1. Ross Levinsohn
    2. Dan Rosensweig
    3. Sheryl Sandberg
    4. Jim Lanzone
    5. David Rosenblatt
    6. Margo Georgiadis
    7. Susan Wojiki
    8. Beth Comstock
    9. Linda Yaccarino
    10. Jason Killar

    Peck pointed out that there was no clarity on what the board and CEO might do, and that the list is merely to address investor questions around the possible candidates.

    “As for next catalysts, we would expect to potentially hear from the company on: the convertible bond notice, a “will” letter from Skadden Arps, and potentially a response to Starboard’s letter. Given the overwhelming likelihood that the Aabaco spin is treated as tax-free, we maintain Buy rating and $40 PT that is based on sum of the parts using 5x 2017 EBITDA,” the SunTrust report stated.

    Latest Ratings for YHOO

    Date Firm Action From To
    Nov 2015 Boenning & Scattergood Initiates Coverage on Outperform
    Oct 2015 Morgan Stanley Maintains Overweight
    Oct 2015 Credit Suisse Maintains Neutral

    View More Analyst Ratings for YHOO
    View the Latest Analyst Ratings

    Posted-In: Bob Peck Marissa MayerAnalyst Color Long Ideas Reiteration Top Stories Analyst Ratings Trading Ideas Best of Benzinga





    Patience May Be Needed In Aratana Therapeutics

    Courtesy of Benzinga.

    Patience May Be Needed In Aratana Therapeutics

    Related PETX
    Morning Market Losers
    UPDATE: AT-005 Benefits In Combination With 2 SPecific Chemotherapy Protocols In 2 Randomized, Placebo-Controlled Studies

  • The share price of Aratana Therapeutics Inc (NASDAQ: PETX) has declined 65.6 percent year-to-date, almost touching its 52-week low on November 19.
  • Barclays’ Douglas D. Tsao has maintained an Overweight rating on the company, while lowering the price target from $30 to $15.
  • Although the stock has continued to underperform, Tsao believes that it could be worthwhile to stay with the story due to the potential of the company’s key assets.
  • Analyst Douglas Tsao elaborated that Aratana Therapeutics has provided details about commercial initiatives associated with its lead products, which have enhanced his confidence in the portfolio.

    However, Tsao also mentioned that despite “the maturation of PETX's towards commercialization, PETX shares have continued to underperform,” while also stating that “clinical catalysts for the lead three assets have provided only ephemeral relief for shares, triggering investor frustration and obviously many to give up.”

    Related Link: Hasbro Launches “Companion Pets” For Seniors

    Potential Ahead

    Tsao believes that it is worthwhile staying with the stock, given that there is potential for lead assets to generate sales of more than $200 million. “We feel particularly bullish for Galliprant which launches in a large, established market with a differentiated profile,” Tsao stated.

    On the other hand, when launched, Entyce would be the only FDA-approved drug for inappetence, catering to a population for about 4.1 million dogs. Nocita is also poised to capitalize on the post-surgery pain market.

    According to the Barclays report, about 6 million dogs undergo painful surgery each year in the United States. “Alternative NSAIDs and opioids pose tolerability and scheduling concerns, unlike the non-opioid formulation of Nocita,” the report mentioned.

    Aratana Therapeutics is expected to look at promoting its products overseas going forward, through partnership. “Mgmt seems patient, waiting for signoff from FDA on three major clinical sections of marketing applications, before signing a deal,” Tsao added.

    Image Credit: Public Domain

    Latest Ratings for PETX

    Date Firm Action From To
    Jul 2015 Lake Street Initiates Coverage on Buy
    Feb 2015 Stifel Nicolaus Maintains Buy
    Feb 2015 Bank of America Initiates Coverage on Buy

    View More Analyst Ratings for PETX
    View the Latest Analyst Ratings

    Posted-In: Barclays Douglas D. Tsao EntyceAnalyst Color Long Ideas Price Target Analyst Ratings Trading Ideas Best of Benzinga





    Paul Craig Roberts Rages At The “Arrogance, Hubris, & Stupidity” Of The US Government

    Courtesy of ZeroHedge. View original post here.

    Submitted by Tyler Durden.

    On the heels of the Chinese stock market plunging 5.5%, continued turmoil in the Middle East and the price of gold hitting 5 year lows, former U.S. Treasury official, Dr. Paul Craig Roberts told Eric King of King World News that Putin and the Russians are now dominating in Syria and the Middle East as the West destroys itself.

    Dr. Paul Craig Roberts:  “It could well be that this is going to work out so much in Russia’s favor that Putin will send a letter of thanks to the Turkish President and say, ‘Thank you very much.  You’ve done us a huge favor. (Laughter).  We lost a pilot and a naval marine but we sure have gained a lot.  That was only two deaths for winning a war.”…

    “So that looks to me like the most likely outcome.  The unintended consequence of this are so positive for Russia that it’s got Washington quaking and Europe wondering about the idiocy of being in NATO.”

    Eric King:  “What I’m hearing from you Russia is dominating in Syria.  The Russians have completely taken over and there’s really nothing Washington can do.”

    Paul Craig Roberts:  “No, except make a fool of itself by supporting ISIS.  We brought ISIS in there (to Syria) — everybody knows that.  Just the other day the former head the Pentagon’s Defense Intelligence Agency said on television that ‘Yes, we created ISIS and we used them as henchmen to overthrow governments.’ (Laughter).

    And the polls in Europe show that the people are on Russia’s side regarding the shooting down of their aircraft.  They don’t believe (the West’s) story at all.  So I think what you are seeing here is the arrogance, hubris, and stupidity of the United States government.  They are just handing every possible advantage over to the Russians.

    This American government is the most incompetent government that has ever walked the earth.  Those people don’t have any sense at all.  Just look at what they’ve done.  In 14 years they’ve destroyed 7 countries, killed millions of people, and displaced millions of people.  And where are those displaced people?  They are overrunning Europe.

    This is all because those Europeans were stupid enough to enable our wars.  Now the political parties in Europe are under tremendous pressure from these refugees and the populations who


    continue reading





     
     
     

    Zero Hedge

    Johns Hopkins, Bristol-Myers Face $1 Billion Suit For Infecting Guatemalan Hookers With Syphilis 

    Courtesy of ZeroHedge. View original post here.

    A federal judge in Maryland said Johns Hopkins University, pharmaceutical company Bristol-Myers Squibb and the Rockefeller Foundation must face a $1 billion lawsuit over their roles in a top-secret program in the 1940s ran by the US government that injected hundreds of Guatemalans with syphilis, reported Reuters.

    Several doctors from Hopkins an...



    more from Tyler

    Phil's Favorites

    This Is The One Chart Every Trader Should Have "Taped To Their Screen"

    Courtesy of Zero Hedge

    After a year of tapering, the Fed’s balance sheet finally captured the market’s attention during the last three months of 2018.

    By the start of the fourth quarter, the Fed had finished raising the caps on monthly roll-off of its balance sheet to the full $50bn per month (peaking at $30bn USTs, $20bn MBS, although on many months the (balance sheet) B/S does not actually shrink by this full amount which depends on the redemption schedule) and by end-Q4 markets also experienced some of the largest volatility and drawdowns in nearly a decade.

    As Nomura&...



    more from Ilene

    ValueWalk

    The Competition For Capital Has Made Stocks Cheap

    By Michelle Jones. Originally published at ValueWalk.

    The new year is upon us, and now is the time many investors look at what 2018 was and prepare for what 2019 might be. Recession jitters are starting to pick back up again, especially now that the full picture of 2018 is in the books. But what if you could pick only one theme for 2018? Jefferies strategist Sean Darby and team have a suggestion which is especially timely given that it appears to mark the end of an era.

    StockSnap / PixabayVolatility carries into the new year

    This past year was one of extremes, and the markets ended i...



    more from ValueWalk

    Kimble Charting Solutions

    Stock declines did not break 9-year support, says Joe Friday

    Courtesy of Chris Kimble.

    We often hear “Stocks take an escalator up and an elevator down!” No doubt stocks did experience a swift decline from the September highs to the Christmas eve lows. Looks like the “elevator” part of the phrase came true as 2018 was coming to an end.

    The first part of the “stocks take an escalator up” seems to still be in play as well despite the swift decline of late.

    Joe Friday Just The Facts Ma’am- All of these indices hit long-term rising support on Christmas Eve at each (1), where support held and rallies have followed.

    If you find long-term perspectives helpf...



    more from Kimble C.S.

    Digital Currencies

    Transparency and privacy: Empowering people through blockchain

     

    Transparency and privacy: Empowering people through blockchain

    Blockchain technologies can empower people by allowing them more control over their user data. Shutterstock

    Courtesy of Ajay Kumar Shrestha, University of Saskatchewan

    Blockchain has already proven its huge influence on the financial world with its first application in the form of cryptocurrencies such as Bitcoin. It might not be long before its impact is felt everywhere.

    Blockchain is a secure chain of digital records that exist on multiple computers simultaneously so no record can be erased or falsified. The...



    more from Bitcoin

    Insider Scoop

    Cars.com Explores Strategic Alternatives, Analyst Sees Possible Sale Price Around $30 Per Share

    Courtesy of Benzinga.

    Related 44 Biggest Movers From Yesterday 38 Stocks Moving In Wednesday's Mid-Day Session ...

    http://www.insidercow.com/ more from Insider

    Chart School

    Weekly Market Recap Jan 13, 2019

    Courtesy of Blain.

    In last week’s recap we asked:  “Has the Fed solved all the market’s problems in 1 speech?”

    Thus far the market says yes!  As Guns n Roses preached – all we need is a little “patience”.  Four up days followed by a nominal down day Friday had the market following it’s normal pattern the past nearly 30 years – jumping whenever the Federal Reserve hints (or essentially says outright) it is here for the markets.   And in case you missed it the prior Friday, Chairman Powell came back out Thursday to reiterate the news – so…so… so… patient!

    Fed Chairman Jerome Powell reinforced that message Thursday during a discussion at the Economic Club of Washington where he said that the central bank will be “fle...



    more from Chart School

    Members' Corner

    Why Trump Can't Learn

     

    Bill Eddy (lawyer, therapist, author) predicted Trump's chaotic presidency based on his high-conflict personality, which was evident years ago. This post, written in 2017, references a prescient article Bill wrote before Trump even became president, 5 Reasons Trump Can’t Learn. ~ Ilene 

    Why Trump Can’t Learn

    Donald Trump by Gage Skidmore (...



    more from Our Members

    Biotech

    Opening Pandora's Box: Gene editing and its consequences

    Reminder: We are available to chat with Members, comments are found below each post.

     

    Opening Pandora's Box: Gene editing and its consequences

    Bacteriophage viruses infecting bacterial cells , Bacterial viruses. from www.shutterstock.com

    Courtesy of John Bergeron, McGill University

    Today, the scientific community is aghast at the prospect of gene editing to create “designer” humans. Gene editing may be of greater consequence than climate change, or even the consequences of unleashing the energy of the atom.

    ...

    more from Biotech

    Mapping The Market

    Trump: "I Won't Be Here" When It Blows Up

    By Jean-Luc

    Maybe we should simply try him for treason right now:

    Trump on Coming Debt Crisis: ‘I Won’t Be Here’ When It Blows Up

    The president thinks the balancing of the nation’s books is going to, ultimately, be a future president’s problem.

    By Asawin Suebsaeng and Lachlan Markay, Daily Beast

    The friction came to a head in early 2017 when senior officials offered Trump charts and graphics laying out the numbers and showing a “hockey stick” spike in the nationa...



    more from M.T.M.

    OpTrader

    Swing trading portfolio - week of September 11th, 2017

    Reminder: OpTrader is available to chat with Members, comments are found below each post.

     

    This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

    We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

    Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

    To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...



    more from OpTrader

    Promotions

    Free eBook - "My Top Strategies for 2017"

     

     

    Here's a free ebook for you to check out! 

    Phil has a chapter in a newly-released eBook that we think you’ll enjoy.

    In My Top Strategies for 2017, Phil's chapter is Secret Santa’s Inflation Hedges for 2017.

    This chapter isn’t about risk or leverage. Phil present a few smart, practical ideas you can use as a hedge against inflation as well as hedging strategies designed to assist you in staying ahead of the markets.

    Some other great content in this free eBook includes:

     

    ·       How 2017 Will Affect Oil, the US Dollar and the European Union

    ...

    more from Promotions





    About Phil:

    Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

    Learn more About Phil >>


    As Seen On:




    About Ilene:

    Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

    Market Shadows >>